

4-5-20
Dory
276-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Canadian Blood Services

Group No.:

Serial No.: Continuation of PCT/CA98/01105

Examiner:

Filed: Herewith

For: METHOD FOR INHIBITING IN VIVO IMMUNE RESPONSE

PRELIMINARY AMENDMENT

Before examination, please amend the above-identified Application as follows:

Please cancel claim 1.

Please add the following new claims:

24. A method for inhibiting an alloimmune response in a patent, comprising the step of administering a therapeutically effective amount of a soluble recombinant human CD40L or a functional fragment thereof containing the active binding site of CD40 and capable of binding thereto.

25. The method of claim 24, wherein the soluble recombinant human CD40L has a sequence comprised in amino acids 108 to 261 of sequence set forth in SEQ ID NO:1.

26. The method of claim 24, wherein the alloimmune response is a human anti-HLA alloimmune response.

27. A method for inhibiting T Cell function in an alloimmune response in a patent, comprising the step of administering a therapeutically effective amount of a soluble recombinant human CD40L or a functional fragment thereof containing the active binding site of CD40 and capable of binding thereto.

28. The method of claim 27, wherein the soluble recombinant human CD40L has a sequence comprised in amino acids 108 to 261 of sequence set forth in SEQ ID NO:1.

29. The method of claim 28, wherein the alloimmune response is a human anti-HLA alloimmune response.